Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

A. Palumbo, SV. Rajkumar, JF. San Miguel, A. Larocca, R. Niesvizky, G. Morgan, O. Landgren, R. Hajek, H. Einsele, KC. Anderson, MA. Dimopoulos, PG. Richardson, M. Cavo, A. Spencer, AK. Stewart, K. Shimizu, S. Lonial, P. Sonneveld, BG. Durie, P....

. 2014 ; 32 (6) : 587-600.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc14063763

PURPOSE: To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. METHODS: A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. RESULTS: Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. CONCLUSION: These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063763
003      
CZ-PrNML
005      
20140709122755.0
007      
ta
008      
140704s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.2013.48.7934 $2 doi
035    __
$a (PubMed)24419113
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Palumbo, Antonio $u Antonio Palumbo and Alessandra Larocca, University of Torino, Torino; Michele Cavo, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Jesus F. San Miguel, University Hospital of Salamanca, Salamanca, Spain; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Gareth Morgan, Royal Marsden Hospital, London, United Kingdom; Ola Landgren, National Cancer Institute, Bethesda, MD; Roman Hajek, University of Ostrava School of Medicine and University Hospital Ostrava, Ostrava, Czech Republic; Hermann Einsele, University of Wurzburg, Wurzburg, Germany; Kenneth C. Anderson and Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Meletios A. Dimopoulos, University of Athens School of Medicine, Athens, Greece; Andrew Spencer, Alfred Hospital, Melbourne, Victoria, Australia; A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Kazuyuki Shimizu, Aichi Gakuin Hospital, Nagoya, Japan; Sagar Lonial, Emory University, Atlanta, GA; Pieter Sonneveld, Erasmus Medical Centre, Rotterdam, the Netherlands; Brian G.M. Durie, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; Philippe Moreau, University Hospital, Nantes, France; and Robert Z. Orlowski, MD Anderson Cancer Center, Houston, TX.
245    10
$a International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation / $c A. Palumbo, SV. Rajkumar, JF. San Miguel, A. Larocca, R. Niesvizky, G. Morgan, O. Landgren, R. Hajek, H. Einsele, KC. Anderson, MA. Dimopoulos, PG. Richardson, M. Cavo, A. Spencer, AK. Stewart, K. Shimizu, S. Lonial, P. Sonneveld, BG. Durie, P. Moreau, RZ. Orlowski,
520    9_
$a PURPOSE: To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. METHODS: A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. RESULTS: Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. CONCLUSION: These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.
650    _2
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a mnohočetný myelom $x diagnóza $x terapie $7 D009101
650    _2
$a paliativní péče $7 D010166
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Rajkumar, S Vincent
700    1_
$a San Miguel, Jesus F
700    1_
$a Larocca, Alessandra
700    1_
$a Niesvizky, Ruben
700    1_
$a Morgan, Gareth
700    1_
$a Landgren, Ola
700    1_
$a Hajek, Roman
700    1_
$a Einsele, Hermann
700    1_
$a Anderson, Kenneth C $7 gn_A_00006159
700    1_
$a Dimopoulos, Meletios A
700    1_
$a Richardson, Paul G
700    1_
$a Cavo, Michele
700    1_
$a Spencer, Andrew
700    1_
$a Stewart, A Keith
700    1_
$a Shimizu, Kazuyuki
700    1_
$a Lonial, Sagar
700    1_
$a Sonneveld, Pieter
700    1_
$a Durie, Brian G M
700    1_
$a Moreau, Philippe
700    1_
$a Orlowski, Robert Z
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 32, č. 6 (2014), s. 587-600
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24419113 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140709123047 $b ABA008
999    __
$a ok $b bmc $g 1031247 $s 862495
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 32 $c 6 $d 587-600 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20140704

Najít záznam

Citační ukazatele

Možnosti archivace